Gene Structure of CYP2C8 and Extrahepatic Distribution of the Human CYP2Cs

Theresa S. Klose,1,2 Joyce A. Blaisdell,1 and Joyce A. Goldstein1

1Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
2Department of Toxicology, North Carolina State University, Raleigh, North Carolina 27695-7633

Received 3 December 1998; revised 4 January 1999; accepted 11 January 1999

Abstract: Extrahepatic tissue distribution of the m-RNAs for the four human CYP2Cs (2C8, 2C9, 2C18, and 2C19) was examined in kidney, testes, adrenal gland, prostate, brain, uterus, mammary gland, ovary, lung, and duodenum. CYP2C mRNAs were detected by RT-PCR using specific primers for each individual CYP2C. CYP2C8 mRNA was detected in the kidney, adrenal gland, brain, uterus, mammary gland, ovary, and duodenum. CYP2C9 mRNA was detected in the kidney, testes, adrenal gland, prostate, ovary, and duodenum. CYP2C18 mRNA was found only in the brain, uterus, mammary gland, kidney, and duodenum and CYP2C19 mRNA was found only in the duodenum. Immunoblot analysis of small intestinal microsomes detected both 2C9 and 2C19 proteins. In addition, genomic clones for CYP2C8 were sequenced, and long-distance PCR was performed to determine the complete gene structure. CYP2C8 spanned a 31 kb region. Comparative analysis of the 2.4 kb upstream region of CYP2C8 with CYP2C9 revealed two previously unidenti®ed transcription factors sites, C/EBP and HPF-1, and the latter might be involved in hepatic expression. Although CYP2C8 has been shown to be phenobarbital inducible, neither a barbiturate-responsive regulatory sequence (a Barbie box) nor a phenobarbital-responsive enhancer module (PBREM) was found within the upstream region analyzed. © 1999 John Wiley & Sons, Inc. J Biochem Toxicol 13: 289±295, 1999

KEYWORDS: CYP2C8 Gene Structure, Human CYP2C mRNA Expression, Extrahepatic Tissues.

INTRODUCTION

Cytochrome P450s are found in abundance in the liver and, to a lesser extent, in extrahepatic tissues. Within the CYP2C subfamily of P450s, cDNAs for four well characterized members, 2C8, 2C9, 2C18, and 2C19, have been isolated and characterized from human liver [1]. The gene structure and upstream regulatory regions for both CYP2C9 and CYP2C18 have been identified and characterized [2]. To date, only the 5' flanking region, exon 1, and the first 840 bp of intron 1 of CYP2C8 have been characterized [3]. Polymorphisms for CYP2C9, CYP2C18, and CYP2C19 have been reported [4±6], but to date no polymorphisms have been associated with CYP2C8.

Different 2C isoforms have been detected in rat, mouse, and porcine liver and extrahepatic tissues [7-10]. Three of these enzymes (2C8, 2C9, and 2C19) have also been identified in human liver [11]. Other investigators have detected some CYP2Cs or their mRNAs in human extrahepatic tissues. Zeldin et al. [12] were able to detect 2C8 and 2C9 (2C10) mRNA in kidney. Hukkanen et al. [13] detected CYP2C mRNA transcripts in bronchoalveolar macrophages using universal CYP2C primers in RT-PCR analysis. Nakajima et al. [14] reported CYP2C8 protein expressed in lung microsomes, and Macé et al. [15] detected both CYP2C8 and CYP2C18 mRNA transcripts in both bronchial mucosa and peripheral lung tissues. CYP2C8 and CYP1A1 mRNA were found to be the most frequently expressed CYP mRNAs in adult brain by McFadyen et al. [16]. CYP2C mRNA forms were detected in breast tissue by Huang et al. [17] with universal CYP2C primers in RT-PCR, but no individual forms were identified. Zaphiropoulos [18] found CYP2C18 mRNA to be abundantly expressed in the adult epidermis. Although no CYP2C mRNA was detected in full term placenta [19], CYP2C mRNA expression using universal CYP2C primers in RT-PCR was identified in first trimester placenta [20].

In this study, the complete gene structure of CYP2C8 was determined by sequencing CYP2C8 genomic clones and by long-distance PCR. In addition, the CYP2C mRNA distribution in human extrahepatic tissues was investigated. To identify the individual is-
TABLE 1. Nucleotide Sequences of PCR Primers

| CYP Isoform | Nucleotide Sequences | Predicted Size of Amplified Fragment (bp) |
|-------------|----------------------|------------------------------------------|
| 2C8 Sense   | AGA TCA GAA TTT TCT CAC CC | 158                                      |
| Antisense   | AAC TTC GTG TAA GAG CAA CA |                                         |
| 2C9 Sense   | AGG AAA AGC ACA ACC AAC CA | 104                                      |
| Antisense   | TCT CAG GGT TGT CTT TGT C |                                         |
| 2C18 Sense  | ACC TCA GGA TTC TGA GCT CT | 142                                      |
| Antisense   | TCT TCT TTT ATT CTC TCC AAT AC |                                    |
| 2C19 Sense  | ATT GAA TGA AAA CAT CAG GAT TG | 182                                      |
| Antisense   | GAG GGT TGT TGA TGT CCA TC |                                         |

oforms, specific primers for the four isoforms were designed and used in RT-PCR analyses. Immunohistochemical analysis for specific CYP2Cs was also performed on small intestinal and lung microsomes to identify which proteins were present.

MATERIALS AND METHODS

Human cDNA Samples

The following tissues were purchased from the International Institute for the Advancement of Medicine (Exton, PA): adrenal gland, testes, and prostate. Kidney and ovary were purchased from National Disease Research Interchange (Philadelphia, PA). Total RNA from these tissues was isolated using TRIzol™ LS Reagent (Life Technologies Inc., Gaithersburg, MD). Total RNAs from brain, uterus, mammary gland, and lung were purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). Total RNA from duodenum was kindly donated by Dr. Paul Watkins (University of Michigan, Ann Arbor, MI) and was prepared by the methods of Chomczynski and Sacchi [21]. cDNA synthesis was performed in a total volume of 100 µL containing 1 µL RNA, 0.3 mM dNTPs, 1 µg Oligo (dT)12-18 Primer (Life Technologies Inc., Gaithersburg, MD), 1 × MMLV-Reverse Transcriptase Buffer (Stratagene, La Jolla, CA), 50 units of MMLV-Reverse Transcriptase, and DEPC-treated water. The RNA and other components were heated at 94°C for 2 minutes prior to the addition of reverse transcriptase. After the addition of reverse transcriptase, the mixture was incubated at 37°C for 90 minutes. The reaction was inactivated by heating at 94°C for 2 minutes.

Amplification of cDNA

The cDNA fragments were amplified using specific CYP2C primers for 2C8, 2C9, 2C18, and 2C19. Primers are shown in Table 1. Amplification was conducted in 1× PCR buffer (67 mM Tris-HCl, pH 8.8, 17 mM (NH4)2SO4, 10 mM β-mercaptoethanol, 7 µM EDTA, 0.2 mg/mL bovine serum albumin) containing 50 µM dNTPs, 0.25 µM concentrations of PCR primers, 2.5 units of AmpliTaq DNA polymerase (Applied Biosystems Inc., Foster City, CA), and 2.0 mM MgCl2. Primers were synthesized using an Applied Biosystems Synthesizer (Applied Biosystems Inc., Foster City, CA). PCR amplification consisted of an initial denaturation step at 94°C for 5 minutes followed by 38 cycles of denaturation at 94°C for 20 seconds, annealing at 55°C for 10 seconds, and an extension at 72°C for 10 seconds. A final extension step at 72°C for 5 minutes was also performed in a Perkin Elmer 9600 GeneAmp PCR system (Perkin Elmer Cetus, Norwalk, CT). The PCR products were checked on a 3% Seakem ME agarose gel (FMC Bioproducts, Rockland, ME).

Immunoblot Analysis of Small Intestinal and Lung Microsomes

Human small intestinal microsomes were kindly donated by Dr. Paul Watkins (University of Michigan, Ann Arbor, MI) and were prepared according to methods of Fitzsimmons and Collins [22]. Lung tissue was obtained from National Disease Research Interchange (Philadelphia, PA). Lung microsomes were prepared by standard methods. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (7.6% acrylamide) was performed as described by Laemmli [23]. The proteins were transferred to nitrocellulose sheets by the method of Towbin et al. [24], and immunoblots probed with a rabbit antibody to CYP2C19, which cross reacts with all four CYP2Cs. Immunoblots were developed using the ECL (enhanced chemiluminescence) Western blotting kit from Amersham (Arlington Heights, IL). Recombinant CYP2C proteins were expressed in Escherichia coli and partially purified as previously described [25].

Direct Sequencing and Long-Distance PCR of CYP2C8

A genomic library was constructed in the Lambda Dash II vector (Stratagene, La Jolla, CA) using liver DNA from an individual phenotyped in vitro as an extensive metabolizer of S-mephenytoin (2). The li-
FIGURE 1. Expression of individual human CYP2C mRNA in various tissues. Expression was examined by RT-PCR using specific CYP2C primers, and amplified products were separated by electrophoresis using 3% agarose gels.

RESULTS AND DISCUSSION

The liver has long been considered to be the primary organ for metabolism of both endogenous and xenobiotic compounds. A vast number of xenobiotic-metabolizing enzymes such as cytochrome P450s, alcohol and aldehyde dehydrogenases, acetylttransferases, and glutathione S-transferases are found expressed in great abundance within the liver itself [26]. However, certain human drug metabolizing enzymes are found in extrahepatic tissues. For instance, CYP1A1 is found primarily in the lung [27], and CYP2J2 is expressed highly in the heart, small intestine, and colon [28,29]. The extrahepatic distribution of the CYP2Cs among tissues has not been systematically characterized. RT-PCR technology was utilized in this study for detecting the different isoforms of the human CYP2Cs present in extrahepatic tissues.

Among the panel of extrahepatic tissues examined in the present study, CYP2C8 mRNA was detected in the kidney, adrenal gland, brain, uterus, mammary gland, and ovary (Figure 1). Expression was highest in the adrenal gland, mammary gland, and kidney, followed by the brain, ovary, and uterus. In our study, detection of 2C8 mRNA was variable in lung even though other investigators were able to detect 2C8 mRNA or protein expression in lung [13±15]. The only tissues in which 2C8 mRNA was not detected were testes and prostate. In contrast, CYP2C9 mRNA was detected only in the kidney, testes, adrenal gland, prostate, and ovary (Figure 1), although Shimada et al. [30] were able to detect 2C9 protein in lung in only one of several pulmonary microsomal samples they examined. The intensity of the PCR product was the strongest with adrenal gland and prostate, and the intensity was weak for the ovary. Expression of CYP2C18 mRNA differed in that it was detected only in the brain, uterus, and mammary gland with a trace seen in the kidney. Although CYP2C19 mRNA was not observed in any of the above extrahepatic tissues, all four CYP2C mRNAs were detected in three separate duodenum cDNAs (Figure 2). The levels of mRNA expression in the duodenum among the 2Cs indicated 2C18 expression to be the greatest followed by 2C9, 2C19, and 2C8.

One interesting finding of this study was the differential levels of expression of 2C8 and 2C9 mRNA in various tissues. Figure 3 shows the differential level of expression for 2C8 and 2C9 mRNA in kidney, adrenal gland, testes, and prostate. Amounts of cDNA used included undiluted as well as serial dilutions of 1:2, 1:4, 1:10, 1:20, and 1:50. CYP2C8 mRNA was a predominant CYP2C RNA in kidney and was detected at all dilutions. However, 2C9 mRNA was only detected at high mRNA concentrations indicating higher levels of expression of 2C8 relative to 2C9 in kidney. Both 2C8 and 2C9 mRNAs were found in the adrenal gland but 2C9 appears to be expressed in somewhat higher quantities. In contrast, both testes and prostate displayed high levels of expression for 2C9 mRNA but expression of 2C8 mRNA was not detected in these tissues.
Interestingly, immunoblot analysis of human small intestinal microsomes revealed the presence of both 2C9 and 2C19 proteins (Figure 4). Kolars et al. [31] detected abundant amounts of 3A4 protein in the small intestine as well. This is of particular interest in terms of omeprazole metabolism in which both 2C19 and 3A4 are the key CYP enzymes involved in omeprazole elimination [32]. Yamazaki et al. [33] determined that the extent to which either 2C19 or 3A4 in liver microsomes contributed to 5-oxidation of omeprazole depended on the amount of each protein present. Neither 2C8 nor 2C18 protein expression was detected in the small intestinal microsomes, although the mRNAs for both are expressed; particularly 2C18 mRNA levels had appeared high. Although, Nakijima et al. [14] reported very faint CYP2C8 protein expression in lung microsomes, we were not able to detect expression of any CYP2C protein in the lung (Figure 5) indicating that if present, the levels must be low. CYP2C18 and CYP2C8 are also recognized weakly by our antibody.

A map of the complete gene organization for CYP2C8 is shown in Figure 6. CYP2C8 spanned approximately a 31 kb region, making it the smallest gene among the known human CYP2C genes, with 2C9 and 2C18 spanning more than 39 and 55 kb, respectively.

**FIGURE 2.** Expression of the individual human CYP2C mRNAs in duodenum. Liver cDNA was used as a positive control. Samples 1-3 are amplified cDNA products from three separate individuals. Expression was examined by RT-PCR using specific CYP2C primers and amplified products were separated by electrophoresis using 3% agarose gels.

**FIGURE 3.** RT-PCR analyses of CYP2C8 and CYP2C9 cDNAs showing different levels of expression in kidney, adrenal gland, testes, and prostate. Lanes 1-6 represent the following dilutions of cDNAs: lane 1 is 1:50, lane 2 is 1:20, lane 3 is 1:10, lane 4 is 1:4, lane 5 is 1:2, and lane 6 is undiluted. The marker is GelMarker™.

**FIGURE 4.** Immunoblot analysis of the CYP2C proteins from two human small intestines. 2C19, 2C18, 2C9, and 2C8 represent recombinant purified proteins and amounts used were 0.25 pmol, 5 pmol, 1 pmol, and 5 pmol, respectively. For a positive control, 8 μg of human liver microsomal protein was used. Samples 1 and 2 contained 80 μg of intestinal protein. Polyclonal antibodies for CYP2C19 cross reacted with all CYP2C proteins.

**FIGURE 5.** Immunoblot analysis of CYP2C proteins in human lung. 2C19, 2C18, 2C9, and 2C8 represent recombinant purified proteins and amounts used were 0.25 pmol, 5 pmol, 1 pmol, and 5 pmol. For a control, 8 μg of human liver microsomal protein was used. Expression of the 2Cs in human lung microsomes was examined at two different amounts (150 and 300 μg of protein).
FIGURE 6. Representation of the structure of the CYP2C8 gene. Long-distance PCR was utilized to determine the intron sizes of CYP2C8 using specific 2C8 exon primers and the GeneAmp® XL PCR kit and protocol as described in the methods. The PCR products were analyzed on a 0.5% agarose gel.

TABLE 2. Location of Intron-Exon Boundaries in CYP2C8

| Intron | Donor                  | Intron Size | Acceptor                |
|--------|------------------------|-------------|-------------------------|
| 1      | TTTCACAAATgtaagtctgc   | 1540        | cccttccagTTCCTAAAAG     |
| 2      | AAAGGAACCTTGGtaggtgcac | 171         | tttatagGAATCAATTTC      |
| 3      | AAAACCAAGGgtgggtgact   | 2300        | aaatctttagCTTCACCCCTG   |
| 4      | ATGGATCCAGgtaaggccaa   | 6000        | tctcttttagGTCTGCAATA    |
| 5      | AATGGAGCAGgtaagatatt   | 11500       | tcaccttagGAAAGGACA      |
| 6      | GAGGTACGACgtagaccac    | 2700        | tcttgtagGTCTGCAATA      |
| 7      | CATCCCCAAGgtaagctgt    | 3800        | tcaccttagGCGACACCCA     |
| 8      | TTCTCACGACgtaatagaa    | 1560        | ttaccttagGAAACGAAT      |

[2]. The intron-exon junctions are shown in Table 2. Intron sequences of CYP2C8 will enable further studies of possible polymorphisms for CYP2C8.

Comparison of the 2.4 kb upstream region as well as the first 500 bases of the 5’-region of intron 1 of CYP2C8 with the previously published sequence of Ged and Beaune [3] revealed a few minor differences. A possible explanation for these differences is that the automated sequencing technology now available is capable of producing more accurate sequencing data.

Comparative analysis of the upstream region of CYP2C8 with that of CYP2C9 revealed that CYP2C8 contains two previously unidentified transcription factor sites. The first site was a C/EBP site at positions –1003 through –995, and the second was an HPF-1 site at positions –148 through –143. HPF-1 sites have been implicated in the liver specific regulation of the rabbit CYP2Cs [34]. In a previous study in our laboratory, the HPF-1 site was also identified as the predominant cis-acting element involved in the positive regulation of the CYP2C9 promoter [35]. Morel et al. [36] found that mRNA content, which hybridized to a 2C8 cDNA, was increased in human hepatocytes after exposure to either phenobarbital or rifampicin, suggesting that CYP2C8 may be a phenobarbital inducible gene. Chang et al. [37] also found that 2C8 protein was increased in primary hepatocytes following phenobarbital exposure. However, a barbiturate-responsive regulatory sequence (Barbie box) [38] identified in CYP2C9 [2] was not identified in the 2.4 kb upstream region of CYP2C8 in the present study. A Barbie box has been suggested to be important in phenobarbital inducibility of certain bacterial P450s [39], although its importance in positive regulation of mammalian P450s is more questionable [40]. Negishi and coworkers [41] identified a –51 bp upstream element as important in the phenobarbital inducibility of the mouse Cyp2B10 gene. This is also found in the 1.7 kb upstream region of the human CYP2B6 gene [42]. Within this region a 16 bp NR1 site has been suggested by Negishi (personal communication) to be the key element in mouse, rat, and human phenobarbital-responsive enhancer module (PBREM). We saw no evidence of this 16 bp site within the 2.4 kb upstream of CYP2C8 sequenced in the present study. However, it is possible that similar elements could exist further upstream.

In conclusion, relative CYP2C expression in extrahepatic tissues was determined with RT-PCR technology. Different CYP2C isoforms were found to be expressed in a variety of extrahepatic tissues at different levels. Both CYP2C9 and CYP2C19 proteins were detected in the small intestine, but no CYP2C proteins were detected in lung. However, the role of each isoform in the metabolism of both endogenous and xenobiotic compounds in extrahepatic tissues has yet to be resolved. The gene structure for CYP2C8 has also been elucidated. Currently there are no polymorphisms known to be associated with CYP2C8. However, the knowledge of the structure and sequence of this gene will allow for further studies of any possible genetic polymorphisms in this enzyme.
Acknowledgments

We thank Dr. Paul Watkins of University of Michigan, Ann Arbor, MI for his kind contributions of the total RNA from human duodenum and of the human small intestinal microsomes. We also thank Mrs. Patricia Linko in our laboratory for performing the immunoblot assays.

REFERENCES

1. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for the human cytochrome P450IIC8 gene in multiple individuals. Biochemistry 1993;32(5):1390. Biochemistry 1991;30(13):3247–3255.

2. de Morais SM, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun 1993;194(1):194–201.

3. Ged C, Beaune P. Isolation of the human cytochrome P-450 11C8 gene: multiple glucocorticoid responsive elements in the 5′ region. Biochim Biophys Acta 1991;1088(3):433–435.

4. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenefield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu125 allele variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6(4):341–349.

5. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4(6):285–299.

6. Mamiya K, Ieiri I, Miyahara S, Imai J, Furumii H, Fukumaki Y, Ninomiya H, Tashiro N, Yamada H, Higuchi S. Association of polymorphisms in the human cytochrome P450IIC8 subfamily [published erratum appears in Biochemistry 1993;32(5):1390]. Biochemistry 1991;30(13):3247–3255.

7. Zaphiropoulos PG. cDNA cloning and regulation of a novel rat cytochrome P450 of the 2C gene subfamily (P450IIIC24). Biochem Biophys Res Commun 1991;180(2):645–651.

8. Zaphiropoulos PG, Wood T. Identification of the major cytochrome P450s of subfamily 2C that are expressed in brain of female rats and in olfactory lobes of ethanol treated male rats. Biochem Biophys Res Commun 1993;193(3):1006–1013.

9. Zaphiropoulos PG. Differential expression of cytochrome P450 2C4 transcripts in rat kidney and prostate: evidence indicative of alternative and possibly trans splicing events. Biochem Biophys Res Commun 1993;192(2):778–786.

10. Zaphiropoulos PG, Skantz A, Eliasson M, Ahlberg MB. Cytochrome P450 genes expressed in porcine ovaries: identification of novel forms, evidence for gene conversion, and evolutionary relationships. Biochem Biophys Res Commun 1995;212(2):433–44.

11. Goldstein JA, Faletto MB, Romkes-Spark M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33(7):1743–1752.

12. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression, and characterization of an endogenous human cytochrome P450 arachidonic acid epoxide hydrolase enzyme. Arch Biochem Biophys 1995;322(1):76–86.

13. Hukkanen J, Hakkola J, Anttila S, Piipari R, Karjalainen A, Pelkonen O, Raunio H. Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 1997;20(2):224–230.

14. Nakajima T, Elovaa E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T. Stereoregulation by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 1994;7(6):891–896.

15. Macé K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfiefer AMA. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur Jour Can 1998;34(6):914–920.

16. McFayden MC, Melvin WT, Murray GI. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol 1998;55(6):825–830.

17. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996;24(8):899–905.

18. Zaphiropoulos PG. Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Molecular and Cellular Biology 1997;17(6):2985–2993.

19. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, Boobis AR, Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996;51(4):403–411.

20. Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Crestell T, Pasanen M. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996;52(2):379–383.

21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156–159, 1987.

22. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitory saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25(2):256–266.

23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5):680-685.

24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. [classical article, 1979]. Biotechnology 1992;24:145–149.

25. Ibeanu GC, Blaisdell J, B. I. Ghanayem BI, Beyeler C, Bouchardy C, Wilkinson GR, Daly P, Daly AK, Goldstein JA. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetic 1998;8:129–135.

26. Hodgson E, Levi PE. Introduction to Biochemical Toxicology. Norwalk, CT: Appleton & Lange 1994.
27. Petruzzelli S, Camus AM, Carrozzi L, Ghelarducci L, Rindi M, Menconi G, Angeletti CA, Ahotupa M, Hietanen E, Aitio A, et al. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res 1988;48(16):4695–4700.

28. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996;271(7):3460–3468.

29. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, Wu S. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol 1997;51(6):931–943.

30. Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng YF, Guengerich FP, Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 1996;24(5):515–522.

31. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4(5):247–259.

32. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996;24(10):1081-1087.

33. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997;283(2):434-442

34. Chen D, Lepar G, Kemper B. A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J Biol Chem 1994;269(7):5420-5427.

35. Ibeanu GC, Goldstein JA. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 1995;34(25):8028–8036.

36. Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A. Expression of cytochrome P450 enzymes in cultured human hepatocytes. Eur J Biochem 1996;191(2):437-444.

37. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57(10):1946–1954.

38. He JS, Fulco AJ. A barbiturate-regulated protein binding to a common sequence in the cytochrome P450 genes of rodents and bacteria. J Biol Chem 1991;266(12):7864–7869.

39. Liang Q, He JS, Fulco AJ. The role of Barbie box sequences as cis-acting elements involved in the barbiturate-mediated induction of cytochromes P450BM-1 and P450BM-3 in Bacillus megaterium. J Biol Chem 1995;270(9):4438–4450.

40. Honkasloski P, Negishi M. Regulatory DNA elements of phenobarbital-responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 1998;12(1):3–9.

41. Honkasloski P, Moore R, Washburn KA, Negishi M. Activation by diverse xenocchemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol Pharmacol 1998;53(4):597–601.

42. Honkasloski P, Negishi M. Characterization of a phenobarbital-responsive enhancer module in mouse P450 CYP2B10 gene. J Biol Chem 1997;272(23):14943-14949.